In vivo efficacy of sivelestat in combination with pazufloxacin against Legionella pneumonia.

Abstract

It is important to regulate excessive inflammation when patients with severe infectious disease are treated. Sivelestat sodium hydrate (sivelestat), a neutrophil elastase inhibitor, is used in the treatment of lung injury but its effect on bacterial pneumonia is unknown. The authors examined the efficacy of sivelestat in combination with a fluoroquinolone in a Legionella pneumophila pneumonia mouse model. The combination therapy did not show a significant survival improvement compared to the treatment with fluoroquinolone alone, but reduced bacteria number and inflammatory cells in the early phase. The combination therapy can contribute to treatment of L. pneumophila pneumonia with protecting lungs.

• Authors: Yoshitomo Morinaga, Katsunori Yanagihara, Nobuko Araki, Koichi Yamada, Masafumi Seki, Koichi Izumikawa, Hiroshi Kakeya, Yoshihiro Yamamoto, Yasuaki Yamada, Shigeru Kohno, Shimeru Kamihira
• Journal: Experimental lung research (Exp Lung Res) Vol. 36 Issue 8 Pg. 484-90 (Oct 2010) ISSN: 1521-0499 [Electronic] England
• PMID: 20939755 (Publication Type: Journal Article)

Chemical References

• Fluoroquinolones
• Oxazines
• Serine Proteinase Inhibitors
• Sulfonamides
• pazufloxacin
• sivelestat
• Leukocyte Elastase
• Glycine

Topics

• Animals
• Bronchoalveolar Lavage Fluid (cytology, microbiology)
• Disease Models, Animal
• Drug Therapy, Combination
• Fluoroquinolones (pharmacology)
• Glycine (analogs & derivatives, pharmacology)
• Legionella pneumophila (drug effects, physiology)
• Legionnaires' Disease (drug therapy, microbiology)
• Leukocyte Elastase (antagonists & inhibitors, metabolism)
• Longevity (drug effects)
• Lung (drug effects, microbiology, pathology)
• Male
• Mice
• Mice, Inbred Strains
• Oxazines (pharmacology)
• Serine Proteinase Inhibitors (pharmacology)
• Sulfonamides (pharmacology)
• Treatment Outcome